好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Transverse Myelitis as a Presenting Sign of Intravascular Lymphoma: A Report of Two Cases
Neuro-oncology
Neuro-oncology Posters (7:00 AM-5:00 PM)
020

Describe cases of intravascular lymphoma (IVL) that presented with transverse myelitis (TM). 

IVL is a neoplastic disorder where lymphoid cells are restricted to lumina of vessels, which results in constricted blood flow and thereby infarction. Central nervous system is most common affected organ with encephalopathy being primary symptom.  Unfamiliarity with IVL and its presentation has resulted in most cases being diagnosed at autopsy.

Case series and literature review

Case (1) Seventy-seven-year-old male presented with paraparesis. MRI showed TM from T10 to conus. Patient responded to pulse steroids, but then declined. Autoimmune, metabolic and infectious markers were unrevealing. Cerebrospinal fluid (CSF) showed elevated protein, elevated IgG index, 13 matched oligoclonal bands (OCBs) and negative flow cytometry/cytology. Serology displayed anemia, thrombocytopenia, low HDL as well as elevated LDH, ferritin, and Beta-2-microglobulin.  MRI showed areas of restricted diffusion in brain. Random skin biopsies confirmed IVL with atypical intravascular CD20+ lymphocytes. Family pursued comfort measures given functional status.

Case (2):  Sixty-eight-year-old female presented with subacute paraparesis. MRI of spine showed a 4.5 mm hyperintense lesion in right lateral cord at T6. Patient had sensory improvement with pulse steroids, but then worsened. MRI brain revealed restricted diffusion in multiple vascular territories. Autoimmune, infectious and neoplastic markers were unrevealing. Serology displayed anemia, low HDL, elevated LDH and elevated Ferritin.  CSF was normal including IgG index, OCBs, and flow cytometry/cytology.  Random skin biopsies were unremarkable. Brain biopsy confirmed IVL with intravascular CD20+ lymphocytes. Patient was treated with rituximab, cyclophosphamide, hydroxydaunorubicin and prednisone. 

IVL should be considered as a cause of TM. Cerebral restricted diffusion, response failure of immune-modulatory therapies, anemia, thrombocytopenia, low HDL as well as elevation in LDH, Ferritin, or Beta-2-Microglboluin should raise suspicion for IVL. Skin biopsies are a safe method of tissue diagnosis. Early identification results in effective treatment.
Authors/Disclosures
Sam Hooshmand, DO (Medical College of Wisconsin)
PRESENTER
Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genetech/Roche. Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi . Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics . Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Hooshmand has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Hooshmand has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TG Therapeutics .
Staley A. Brod, MD (Staley Brod, MD) Dr. Brod has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Brod has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi.
Ahmed Z. Obeidat, MD, PhD (Medical College of Wisconsin) Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Obeidat has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Genentech. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Obeidat has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi/Genzyme . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon pharmaceuticals . Dr. Obeidat has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sandoz. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Obeidat has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Alexion. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Obeidat has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Obeidat has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for EMD Serono. Dr. Obeidat has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Banner life sciences . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi/genzyme. Dr. Obeidat has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Horizon therapeutics . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for TG Therapeutics . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AstraZeneca. The institution of Dr. Obeidat has received research support from NIH. The institution of Dr. Obeidat has received research support from NMSS and PCORI. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Expert opinion and key opinion leader with MJH life sciences . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Faculty Speaker with CMSC. Dr. Obeidat has a non-compensated relationship as a Board member with CMSC that is relevant to AAN interests or activities. Dr. Obeidat has a non-compensated relationship as a Editorial Board Member with IJMSC that is relevant to AAN interests or activities. Dr. Obeidat has a non-compensated relationship as a Reviewer Editor with Frontiers Neurology that is relevant to AAN interests or activities. Dr. Obeidat has a non-compensated relationship as a Board of Trustee Member with National MS Society that is relevant to AAN interests or activities.